Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience

This study aimed to determine the real-world, long-term prognostic impacts, and adverse effects (AEs) of bevacizumab (BEV) in Asian patients with ovarian/tubal/peritoneal cancers. We retrospectively reviewed the medical records of consecutive patients with ovarian/tubal/peritoneal cancer on front-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Pei-Ying, Cheng, Ya-Min, Shen, Meng-Ru, Chen, Yi-Chun, Huang, Yu-Fang, Chou, Cheng-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372289/
https://www.ncbi.nlm.nih.gov/pubmed/32760668
http://dx.doi.org/10.3389/fonc.2020.01095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372289/
https://www.ncbi.nlm.nih.gov/pubmed/32760668
http://dx.doi.org/10.3389/fonc.2020.01095

Ejemplares similares